Tazanolast is a selective mast-cell-stabilizing agent, on ozone-induced airway hyperresponsiveness in guinea pigs.In VitroTazanolast, mast-cell-stabilizing drug, which has been shown to suppress passive cutaneous anaphylaxis, Schultz-Dale reaction in isolated tracheal muscle, and experimental asthma without antagonistic actions upon histamine- and leukotriene-D4-induced contraction, IgE-mediated or compound 48/80-induced histamine release from mast cells and lung fragments, compound 48/80-induced Ca 2+ uptake into mast cells from extracellular medium, compound 48/80-induced translocation of protein kinase C from the cytosol to the membrane fraction of mast cells, and inositol trisphosphate production without directly inhibiting phospholipase C in mast cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoTazanolast administered before ozone exposure at doses of 30, 100, or 300 mg/kg inhibits ozone-induced airway hyperresponsiveness in a dose-dependent manner. Tazanolast administered after ozone exposure does not inhibit the airway hyperresponsiveness. Tazanolast does not significantly change the cell distribution of bronchoalveolar lavage (BAL) cells at 2 h after the exposure. Tazanolast significantly inhibits ozone-induced airway hyperresponsiveness in guinea pigs . MCE has not independently confirmed the accuracy of these methods. They are for reference only.Form:Solid
Specification: ≥99%
Molecular Formula: C13H15N5O3
Molecular Weight: 289.29
PubChem CID: 5380
Isomeric SMILES: CCCCOC(=O)C(=O)NC1=CC=CC(=C1)C2=NNN=N2
- UPC:
- 51161528
- Condition:
- New
- Availability:
- 4-8 weeks
- Weight:
- 0.07 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- T648211-5mg
- CAS:
- 82989-25-1
- Product Size:
- 5mg
